Biopersistence and potential adverse health impacts of fibrous nanomaterials: what have we learned from asbestos?
Human diseases associated with exposure to asbestos fibers include pleural fibrosis and plaques, pulmonary fibrosis (asbestosis), lung cancer, and diffuse malignant mesothelioma. The critical determinants of fiber bioactivity and toxicity include not only fiber dimensions, but also shape, surface reactivity, crystallinity, chemical composition, and presence of transition metals. Depending on their size and dimensions, inhaled fibers can penetrate the respiratory tract to the distal airways and into the alveolar spaces. Fibers can be cleared by several mechanisms, including the mucociliary escalator, engulfment, and removal by macrophages, or through splitting and chemical modification. Biopersistence of long asbestos fibers can lead to inflammation, granuloma formation, fibrosis, and cancer. Exposure to synthetic carbon nanomaterials, including carbon nanofibers and carbon nanotubes (CNTs), is considered a potential health hazard because of their physical similarities with asbestos fibers. Respiratory exposure to CNTs can produce an inflammatory response, diffuse interstitial fibrosis, and formation of fibrotic granulomas similar to that observed in asbestos-exposed animals and humans. Given the known cytotoxic and carcinogenic properties of asbestos fibers, toxicity of fibrous nanomaterials is a topic of intense study. The mechanisms of nanomaterial toxicity remain to be fully elucidated, but recent evidence suggests points of similarity with asbestos fibers, including a role for generation of reactive oxygen species, oxidative stress, and genotoxicity. Considering the rapid increase in production and use of fibrous nanomaterials, it is imperative to gain a thorough understanding of their biologic activity to avoid the human health catastrophe that has resulted from widespread use of asbestos fibers.
Sanchez
Vanesa C
VC
Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA.
Pietruska
Jodie R
JR
Miselis
Nathan R
NR
Hurt
Robert H
RH
Kane
Agnes B
AB
D000818:Animals; D001194:Asbestos / Q000493:pharmacokinetics / Q000506:poisoning / Q000633:toxicity; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced / Q000378:metabolism; D051379:Mice; D049329:Nanostructures / Q000506:poisoning* / Q000633:toxicity / Q000648:ultrastructure
D001194:Asbestos